Literature DB >> 28017827

Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease.

Hiroko H Dodge1, Jian Zhu2, Randy Woltjer3, Peter T Nelson4, David A Bennett5, Nigel J Cairns6, David W Fardo7, Jeffrey A Kaye8, Deniz-Erten Lyons8, Nora Mattek3, Julie A Schneider9, Lisa C Silbert8, Chengjie Xiong10, Lei Yu5, Frederick A Schmitt11, Richard J Kryscio7, Erin L Abner12.   

Abstract

INTRODUCTION: The presence of cerebrovascular pathology may increase the risk of clinical diagnosis of Alzheimer's disease (AD).
METHODS: We examined excess risk of incident clinical diagnosis of AD (probable and possible AD) posed by the presence of lacunes and large infarcts beyond AD pathology using data from the Statistical Modeling of Aging and Risk of Transition study, a consortium of longitudinal cohort studies with more than 2000 autopsies. We created six mutually exclusive pathology patterns combining three levels of AD pathology (low, moderate, or high AD pathology) and two levels of vascular pathology (without lacunes and large infarcts or with lacunes and/or large infarcts).
RESULTS: The coexistence of lacunes and large infarcts results in higher likelihood of clinical diagnosis of AD only when AD pathology burden is low. DISCUSSION: Our results reinforce the diagnostic importance of AD pathology in clinical AD. Further harmonization of assessment approaches for vascular pathologies is required.
Copyright © 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease pathology; Community sample; Population Attributable Risk%; SMART consortium; Vascular pathology

Mesh:

Substances:

Year:  2016        PMID: 28017827      PMCID: PMC5466467          DOI: 10.1016/j.jalz.2016.11.003

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  53 in total

1.  Multiple imputation for missing data via sequential regression trees.

Authors:  Lane F Burgette; Jerome P Reiter
Journal:  Am J Epidemiol       Date:  2010-09-14       Impact factor: 4.897

2.  The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old.

Authors:  M S Green; J A Kaye; M J Ball
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

3.  Ecology of the aging human brain.

Authors:  Joshua A Sonnen; Karen Santa Cruz; Laura S Hemmy; Randall Woltjer; James B Leverenz; Kathleen S Montine; Clifford R Jack; Jeffrey Kaye; Kelvin Lim; Eric B Larson; Lon White; Thomas J Montine
Journal:  Arch Neurol       Date:  2011-08

4.  Vascular burden and Alzheimer disease pathologic progression.

Authors:  Raymond Y Lo; William J Jagust
Journal:  Neurology       Date:  2012-09-12       Impact factor: 9.910

5.  University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology.

Authors:  Frederick A Schmitt; Peter T Nelson; Erin Abner; Stephen Scheff; Gregory A Jicha; Charles Smith; Gregory Cooper; Marta Mendiondo; Deborah D Danner; Linda J Van Eldik; Allison Caban-Holt; Mark A Lovell; Richard J Kryscio
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

6.  Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease.

Authors:  Sukriti Nag; Lei Yu; Ana W Capuano; Robert S Wilson; Sue E Leurgans; David A Bennett; Julie A Schneider
Journal:  Ann Neurol       Date:  2015-04-22       Impact factor: 10.422

7.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

8.  Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons.

Authors:  Patricia A Boyle; Lei Yu; Sukriti Nag; Sue Leurgans; Robert S Wilson; David A Bennett; Julie A Schneider
Journal:  Neurology       Date:  2015-11-04       Impact factor: 9.910

9.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

10.  Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Thomas Arzberger; Safa Al-Sarraj; Istvan Bodi; Nenad Bogdanovic; Heiko Braak; Orso Bugiani; Kelly Del-Tredici; Isidro Ferrer; Ellen Gelpi; Giorgio Giaccone; Manuel B Graeber; Paul Ince; Wouter Kamphorst; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; Sergey Larionov; David Meyronet; Camelia Monoranu; Piero Parchi; Efstratios Patsouris; Wolfgang Roggendorf; Danielle Seilhean; Fabrizio Tagliavini; Christine Stadelmann; Nathalie Streichenberger; Dietmar R Thal; Stephen B Wharton; Hans Kretzschmar
Journal:  Brain Pathol       Date:  2008-03-26       Impact factor: 6.508

View more
  11 in total

1.  Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment.

Authors:  Ming Lin; Pinghua Gong; Tao Yang; Jieping Ye; Roger L Albin; Hiroko H Dodge
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Jan-Mar       Impact factor: 2.703

Review 2.  Cerebrovascular Alterations in Alzheimer Disease.

Authors:  Costantino Iadecola; Rebecca F Gottesman
Journal:  Circ Res       Date:  2018-08-03       Impact factor: 17.367

3.  Brain arterial dilatation and the risk of Alzheimer's disease.

Authors:  Jose Gutierrez; Vanessa Guzman; Farid Khasiyev; Jennifer Manly; Nicole Schupf; Howard Andrews; Richard Mayeux; Adam M Brickman
Journal:  Alzheimers Dement       Date:  2019-03-01       Impact factor: 21.566

4.  Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease.

Authors:  Jill K Morris; Roxanne Adeline Z Uy; Eric D Vidoni; Heather M Wilkins; Ashley E Archer; John P Thyfault; John M Miles; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  "Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?

Authors:  John C S Breitner; Hiroko H Dodge; Zaven S Khachaturian; Ara S Khachaturian
Journal:  Alzheimers Dement       Date:  2022-03-04       Impact factor: 16.655

6.  Person-specific contribution of neuropathologies to cognitive loss in old age.

Authors:  Patricia A Boyle; Lei Yu; Robert S Wilson; Sue E Leurgans; Julie A Schneider; David A Bennett
Journal:  Ann Neurol       Date:  2018-01-14       Impact factor: 10.422

Review 7.  Religious Orders Study and Rush Memory and Aging Project.

Authors:  David A Bennett; Aron S Buchman; Patricia A Boyle; Lisa L Barnes; Robert S Wilson; Julie A Schneider
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

8.  Letter.

Authors:  Ara S Khachaturian
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-21

9.  Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery.

Authors:  David A Bennett
Journal:  PLoS Med       Date:  2017-03-14       Impact factor: 11.069

10.  Hierarchical Clustering Analyses of Plasma Proteins in Subjects With Cardiovascular Risk Factors Identify Informative Subsets Based on Differential Levels of Angiogenic and Inflammatory Biomarkers.

Authors:  Zachary Winder; Tiffany L Sudduth; David Fardo; Qiang Cheng; Larry B Goldstein; Peter T Nelson; Frederick A Schmitt; Gregory A Jicha; Donna M Wilcock
Journal:  Front Neurosci       Date:  2020-02-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.